Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Dacomitinib and Erlotinib in NSCLC

Comparing survival and safety

Publish date:: January 19, 2016

Dacomitinib is an active agent with comparable efficacy to erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC), according to a study of 121 patients with any EGFR mutation, including 101 with activating mutations in exon 19 or 21. Researchers found:

In patients with exon 19/21 mutations, median progression-free survival was 14.6 months with dacomitinib and 9.6 months with erlotinib.

Median survival was 26.6 months with dacomitinib vs 23.2 months with erlotinib.

Dacomitinib was associated with higher incidence of diarrhea and mucositis vs erlotinib.

Citation: Ramalingam SS, O’Byrne K, Boyer M, et al. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. [Published online ahead of print January 13, 2016]. Ann Oncol. doi: 10.1093/annonc/mdv593.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lung Cancer

Two different radiation boost strategies reduce local failures in NSCLC,

Rechallenge ‘reasonable’ for some with small-cell lung cancer,

Black patients with ES-SCLC get less chemo but have better survival,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,